shadow_tr

Prostate Studies
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -


P12-1
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (PREDICT)
More Information

BAY 16544
A Randomized Open-label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination with Abiraterone Acetate or Enzalutamide in Subjects with CRPC Who Have Bone Metastases
More Information

BNIT-PRV-301
A Randomized, Double-Blind, Phase III Efficacy Trial of PROSTVAC-V/F Plus or Minus GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
More Information

RTOG 0534
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With Rising PSA After Radical Prostatectomy
More Information


RTOG 0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
More Information


RTOG 0924
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy In Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
More Information


TUHC 07/25/13 - Genetics of Prostate Cancer


ALLIANCE A031201

Phase III Trial of Enzalutamide (NSC#766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
More Information

BAY 15396
A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
More Information

SWOG S1216
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
More Information

 

1430 Tulane Ave, New Orleans, LA 70112 504-988-5263 medsch@tulane.edu